Current Primary Research

|   Treatment of Chronic Pain  |   Proteomic Markers of Alcohol Abuse  |

Kindolor® Brief Summary

Lohocla Research Corporation rationally designed a novel small molecule named Kindolor for treatment of chronic pain syndromes.  The molecule simultaneously reduces the over-activity of NMDA (NR1-NR2B) receptors and the Nav 1.7 and Nav 1.8 sodium channels in chronic pain syndromes. Kindolor is also an agonist and the delta opioid receptor.   Kindolor has negligible blood brain barrier penetrance which would reduce deleterious CNS side effects. Thus, Kindolor’s actions are confined to the peripheral nervous system. Kindolor’s proof of concept has been established and shows that it produces significant anti-hyperalgesia properties in four animal models of chronic pain.  The metabolic fate of profile of Kindolor is via glucuronidation and hydroxylation.  No genotoxic effects of Kindolor have been noted.  Acute dosing levels 50 times higher than doses producing therapeutic effects produced no overt signs of toxicity and we estimate the therapeutic index for Kindolor to be greater than 50. Following a second non-rodent species one month toxicity study, we plan to open a US IND and begin clinical testing within a year.

pdf icon Learn more

top of page


Proteomic Markers of Alcohol Abuse

Despite the prevalence of alcohol-related problems among medical patients, less than half are identified and even fewer are treated. There is a need for better diagnostics to identify patients who are abusing alcohol, in addition to the need for better therapeutics. Such markers of alcohol consumption will be useful in screening for problematic and hazardous drinking, determining whether a health problem has an alcohol-abuse or dependency component, and monitoring alcoholics for relapse during and after therapeutic intervention.

Lohocla has assessed over 1,000 samples (plasma, serum, and platelets) from individuals well-characterized regarding alcohol consumption, other drug use, medical/psychiatric disorders, and family psychiatric history. Lohocla is using a novel shot-gun proteomics technology to identify and quantify platelet and plasma proteins. The goal is to identify and validate better diagnostic markers appropriate for monitoring level and/or recency of alcohol use, as well as markers for predisposition to alcohol dependence.

The initial set of state markers discovered with this process included the MAO-B protein concentration in platelet membranes. Lower levels have been demonstrated to be diagnostic for hazardous and harmful alcohol intake during a prior week. The marker provides as good or better accuracy than any currently available markers. Additional state and trait markers have been identified as part of this effort.

Lohocla plans to continue to evaluate additional population of subjects to establish accurate estimates of the sensitivity and specificity of the candidate marker proteins to identify level of alcohol intake and/or individuals classified as being high-risk alcohol drinkers or alcohol dependent across a spectrum of ethnic and genetically diverse populations.

pdf icon Learn more

top of page